English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 15 November 2021, 17:15 HKT/SGT
Share:
    

Source: Legend Capital
Aohua Endoscopy, a Leading Endoscope Company Invested by Legend Capital, Successfully Listed on China's STAR Market

HONG KONG, Nov 15, 2021 - (ACN Newswire) - On November 15th, Aohua Endoscope (688212.SH), invested by Legend Capital, was successfully listed on the Science and Technology Innovation Board (STAR Market) in China. The total number of public offering of Aohua Endoscopy is 33.34 million shares with an offering price set at RMB22.5 per share.

Founded in 1994, Aohua Endoscopy is one of the earliest high-tech enterprises in China that mainly engaged in the R&D, production and sales of endoscopes and endoscopic consumables. Aohua Endoscopy's vision is "Becoming the world's leading provider of overall endoscopy solutions". In the course of over 20 years of research and innovation, Aohua Endoscopy has developed a full range of endoscopy products used in various clinical sections, including gastroenterology, pneumology, otorhinolaryngologic and gynecology departments and EDs.

Legend Capital exclusively invested in Aohua Endoscopy's Series B financing in 2014 and co-led its Series C financing in 2016, becoming its largest institutional investor. After the investment, Legend Capital provided all-round support and assistance in its follow-up financing, executive recruitment, and industrial resource docking.

Jafar Wang, the Co-Chief Investment Officer of Legend Capital, said that, Legend Capital adheres to three investment principles: early, long-term and innovative investment. In the field of medical devices, we closely keep pace with the international technological breakthroughs and dig out home companies with fast-follow and even tight-follow technology platforms and products. It's our top priority to focus on cutting-edge R&D worldwide, actively discover entrepreneurs with strong technical strength in related fields, and support them to carry out the above-mentioned fast-follow and even new technological revolution.

Joe Zhou, the Managing Director of Legend Capital, said that, minimally invasive/non-invasive technique is the new trend, while soft endoscopes are the core and technical commanding heights with a global market size reaching USD4 billion. The soft endoscopes technique in Aohua Endoscopy enjoys significant barriers and sustainable market competitiveness. As recent years see rapid growth in overseas sales, Aohua Endoscopy has enriched its product line and expanded its business to consumables. It is believed that after listing, Aohua Endoscopy will further increase R&D investment and boost its global presence, becoming a world-class endoscope company.

Medical devices have always been Legend Capital's vital investment field. Apart from Aohua Endoscopy, Legend Capital's four portfolio companies in the field have gone public successfully this year, including CareRay Digital Medical (688607.SH), a leading company in flat panel detector industry, New Horizon Health (06606.HK), the first public listed cancer screening company in China, Chemclin Diagnostics Corporation (688468.SH), the clinical immunology diagnostic product company, and Singular Genomics (NASDAQ: OMIC), an innovative sequencing technology research and development company.



Topic: Press release summary
Source: Legend Capital

Sectors: BioTech, Healthcare & Pharm, PE, VC & Alternatives
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Legend Capital Releated News
Dec 16, 2021 16:52 HKT/SGT
君联资本所投企业顺丰同城成功登陆港交所
Dec 16, 2021 16:51 HKT/SGT
君聯資本所投企業順豐同城成功登陸港交所
Dec 16, 2021 16:50 HKT/SGT
Legend Capital's Portfolio Company SF Intra-city Successfully Listed on HKEx
Nov 19, 2021 18:43 HKT/SGT
君联资本领投赛纳三维Pre-A轮融资
Nov 19, 2021 18:42 HKT/SGT
君聯資本領投賽納三維Pre-A輪融資
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575